NCT01582516View on ClinicalTrials.gov

Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Brain TumorRecurring Glioblastoma
Interventions
BIOLOGICAL

delta-24-RGD adenovirus

slow continuous microinfusion in and around the brain tumor during 44 hrs.by 4 temporary placed catheters

Trial Locations (1)

Unknown

ERasmus Medical Center, Rotterdam

Sponsors
All Listed Sponsors
collaborator

Amsterdam UMC, location VUmc

OTHER

lead

Erasmus Medical Center

OTHER